Connect with us


Fraser Health declares COVID-19 outbreaks at Baillie House and Bevan Lodge –



FRASER Health on Thursday declared COVID-19 outbreaks at Baillie House in Maple Ridge, and Bevan Lodge in Abbotsford.

Seven residents and five staff members at Baillie House, and nine residents and three staff members at Bevan Lodge have tested positive for COVID-19.

Baillie House is a long-term care facility that is owned and operated by Fraser Health. Bevan Lodge is a long-term care facility that is owned and operated by Trillium Communities. The residents and staff members are currently in self-isolation at their homes.

Enhanced control measures have been put in place at Baillie House. Fraser Health is working to identify anyone who may have been exposed and is taking steps to protect the health of all staff, residents and families.

Fraser Health has worked with Bevan Lodge to support the implementation of enhanced control measures. Fraser Health is also working with the site to identify anyone who may have been exposed, and is taking steps to protect the health of all staff, residents and families.

Adblock test (Why?)

Source link

Continue Reading


What vaccines, treatments do we have to combat monkeypox? – Financial Post



Article content

LONDON — With cases of monkeypox inexplicably on the rise outside of Africa – where the viral disease is endemic – public health officials are using contact tracing, isolation and targeted vaccination to curb its spread.

Global health officials have tracked more than 200 suspected and confirmed cases of the usually mild viral infection in 19 countries since early May. The monkeypox variant implicated in the current outbreak has a case fatality rate of around 1%, though no deaths have been reported so far.

Advertisement 2

Article content

Here’s what we know about the existing range of vaccines and treatments:


The smallpox and monkeypox viruses are closely related, and the first generation of smallpox vaccines appear up to 85% effective in preventing monkeypox, the World Health Organization has said.

There are currently two smallpox vaccines available.

One made by Danish company Bavarian Nordic goes by the brand name Jynneos, Imvamune or Imvanex – depending on geography.

It contains a weakened form of the vaccinia virus that is closely related to, but less harmful than, than the viruses that cause smallpox and monkeypox. This modified version of vaccinia does not cause disease in humans and cannot reproduce in human cells.

It has U.S. approval for the prevention of both smallpox and monkeypox. European Union approval is for smallpox, although doctors can prescribe it off-label for monkeypox. Bavarian Nordic said it would probably apply for a label extension with the EU’s drug watchdog to include monkeypox.

Advertisement 3

Article content

The reported side-effects include pain and swelling at the injection site as well as headache and fatigue.

The other, older vaccine, currently made by Emergent Biosolutions, is called ACAM2000.

It also contains the vaccinia virus, but it is infectious and can replicate in humans. As a result, it can be transmitted from the vaccine recipient to unvaccinated people who have close contact with the inoculation site.

Apart from side-effects associated with many vaccines, such as a sore arm and fatigue, it also carries a serious warning for a potential range of severe complications, including heart inflammation, blindness and death.

It is also not designed to be used in certain groups of people, such as those with compromised immune systems.

Advertisement 4

Article content

ACAM2000 has U.S. approval for people at high risk for smallpox infection. It does not have EU authorisation.


Symptoms of monkeypox – which can include fever, headaches, distinctive rashes and pus-filled skin lesions – can last for two to four weeks and often resolve on their own.

Patients may receive extra fluids and treatment for secondary bacterial infections. An antiviral agent called tecovirimat – branded as TPOXX and made by SIGA Technologies – has U.S. and EU approval for smallpox, while its European approval also includes monkeypox and cowpox.

Another drug, branded as Tembexa and developed by Chimerix , has U.S. approval to treat smallpox. It is not clear whether it could help people infected with monkeypox.

Advertisement 5

Article content

Both TPOXX and Tembexa were approved based on studies in animals showing they are likely to be effective, because they were developed after smallpox in human beings had been eradicated through mass vaccination.


The WHO classified smallpox as an eradicated disease in 1980, but there have been longstanding concerns that the virus could be used as a bioweapon, leading countries to stockpile vaccines.

The WHO holds 2.4 million doses at its Swiss headquarters dating from the final years of the eradication program. The agency also has pledges from donor countries for more than 31 million additional doses.

U.S. officials say there are more than 1,000 doses of the Bavarian Nordic vaccine in the national stockpile and expect that level to ramp up very quickly in the coming weeks. The country also has 100 million doses of ACAM2000.

Advertisement 6

Article content

Germany has said it had ordered 40,000 doses of Bavarian Nordic’s vaccine, to be ready to vaccinate contacts of cases if needed.

Other countries, including Britain and France, are also offering or recommending vaccines to people with close contact to infected people and healthcare workers.

Bavarian Nordic, which has an annual production capacity of 30 million doses, told Reuters multiple countries have approached it interested in buying its vaccine, without providing details. A spokesperson said it does not need to expand production.

(Reporting by Natalie Grover in London; Twitter @NatalieGrover; Additional reporting by Nikolaj Skydsgaard in Copenhagen and Michael Erman in New Jersey; editing by Michele Gershberg, Josephine Mason and Jane Merriman)



Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Adblock test (Why?)

Source link

Continue Reading


Scientists concerned over rising case of monkeypox: How does the virus spread? – India Today



The Monkeypox virus has now been reported from 20 countries of the world, where the viral infection is not endemic. This is one of the biggest outbreaks of the virus outside of West Africa, where it has been endemic for years. The virus has been reported in over 100 people as countries look to get ready for a counterattack with vaccines.

Also Read | Texas school shooting: Teen opened fire on grandma before killing 19 kids, teachers

The cases have now been reported in the US, the UK, Australia, Austria, Belgium, Denmark, Finland, France, Italy among others. So far, no cases have been reported in India.

While the US has said that it has a smallpox vaccine stockpile in case of an outbreak, Germany has ordered 40,000 doses of a Bavarian Nordic vaccine to be ready to vaccinate contacts of those infected with monkeypox if an outbreak in Germany becomes more severe. The fast pace of transmission has baffled scientists, who have raised alarm bells over the developments.

The monkeypox cases so far have been mild. (Photo: Reuters)


Monkeypox is a virus that originates in wild animals like rodents and primates, and occasionally jumps to people. It belongs to the same virus family as smallpox.

The virus transmits when a person comes in contact with the virus from an animal, human, or materials contaminated with the virus. According to the US Based Centre for Disease Control and Prevention (CDC), the virus enters the body through broken skin (even if not visible), respiratory tract, or the mucous membranes (eyes, nose, or mouth). Meanwhile, Animal-to-human transmission may occur by bite or scratch, bush meat preparation, direct contact with body fluids or lesion material, or indirect contact with lesion material, such as through contaminated bedding.

Scientists are also looking into human-to-human contact behind the rise in cases of the monkeypox virus. A World Health Organisation (WHO) has also speculated sexual activity at two recent raves in Europe to be the reason of the spread.

Also Read | ‘This baby is yours’! Woman tells Johnny Depp in courtroom amid Amber Heard trial

A child affected by monkeypox, sits on his father’s legs while receiving treatment at the centre of the International medical NGO Doctors Without Borders (Medecins sans frontieres – MSF), in Zomea Kaka, in the Lobaya region, in the Central African Republic. (Photo: AFP)

Dr. David Heymann, who formerly headed WHO’s emergencies department, told The Associated Press that the leading theory to explain the spread of the disease was sexual transmission at raves held in Spain and Belgium.

Also Read | Anand Mahindra shares a million-dollar life lesson with a video

The CDC does state that while human-to-human transmission is thought to occur primarily through large respiratory droplets, other methods of transmission include direct contact with body fluids or lesion material, and indirect contact with lesion material, such as through contaminated clothing or linens.

The monkeypox cases so far have been mild, with no deaths reported. Typically, the virus causes fever, chills, rash and lesions on the face or genitals. Most people recover within several weeks without requiring hospitalization.

Adblock test (Why?)

Source link

Continue Reading


Monkeypox isn't like COVID-19 — and that's a good thing – KCCU



The recent headlines about a sudden emergence of an unusual disease, spreading case by case across countries and continents may, for some, evoke memories of early 2020.

But monkeypox is no COVID-19 — in a good way.

Health officials worldwide have turned their attention to a new outbreak of monkeypox, a virus normally found in central and west Africa that has appeared across Europe and the U.S. in recent weeks — even in people who have not traveled to Africa at all.

But experts say that, while it’s important for public health officials to be on the lookout for monkeypox, the virus is extremely unlikely to spin out into an uncontrolled worldwide pandemic in the same way that COVID-19 did.

“Let’s just say right off the top that monkeypox and COVID are not the same disease,” said Dr. Rosamund Lewis, head of Smallpox Secretariat at the World Health Organization, at a public Q&A session on Monday.

For starters, monkeypox spreads much less easily than COVID-19. Scientists have been studying monkeypox since it was first discovered in humans more than 50 years ago. And its similarities to smallpox mean it can be combated in many of the same ways.

As a result, scientists are already familiar with how monkeypox spreads, how it presents, and how to treat and contain it — giving health authorities a much bigger head start on containing it.

Here are some of the other ways the public health approach to monkeypox is different from COVID-19:

Scientists already know how it spreads, and it’s different than COVID

Monkeypox typically requires very close contact to spread — most often skin-to-skin contact, or prolonged physical contact with clothes or bedding that was used by an infected person.

By contrast, COVID-19 spreads quickly and easily. Coronavirus can spread simply by talking with another person, or sharing a room, or in rare cases, being inside a room that an infected person had previously been in.

“Transmission is really happening from close physical contact, skin-to-skin contact. It’s quite different from COVID in that sense,” said Dr. Maria Van Kerkhove, an infectious disease epidemiologist with the WHO.

The classic symptom of monkeypox is a rash that often begins on the face, then spreads to a person’s limbs or other parts of the body.

“The incubation from time of exposure to appearance of lesions is anywhere between five days to about 21 days, so can be quite long,” said Dr. Boghuma Kabisen Titanji, an infectious disease physician and virologist at Emory University in Atlanta.

The current outbreak has seen some different patterns, experts say — particularly, that the rash begins in the genital area first, and may not spread across the body.

Either way, experts say, it is typically through physical contact of that rash that the virus spreads.

“It’s not a situation where if you’re passing someone in the grocery store, they’re going to be at risk for monkeypox,” said Dr. Jennifer McQuiston of the Centers for Disease Control and Prevention, in a briefing Monday.

The people most likely to be at risk are close personal contacts of an infected person, such as household members or health care workers who may have treated them, she said.

“We’ve seen over the years that often the best way to deal with cases is to keep those who are sick isolated so that they can’t spread the virus to close family members and loved ones, and to follow up proactively with those that a patient has contact with so they can watch for symptoms,” McQuiston said.

With this version of virus, people generally recover in two to four weeks, scientists find, and the death rate is less than 1%.

Monkeypox is less contagious than COVID-19

One factor that helped COVID-19 spread rapidly across the globe was the fact that it is very contagious. That’s even more true of the variants that have emerged in the past year.

Epidemiologists point to a disease’s R0 value — the average number of people you’d expect an infected person to pass the disease along to.

For a disease outbreak to grow, the R0 must be higher than 1. For the original version of COVID-19, the number was somewhere between 2 and 3. For the omicron variant, that number is about 8, a recent study found.

Although the recent spread of monkeypox cases is alarming, the virus is far less contagious than COVID-19, according to Jo Walker, an epidemiologist at Yale School of Public Health.

“Most estimates from earlier outbreaks have had an R0 of less than one. With that, you can have clusters of cases, even outbreaks, but they will eventually die out on their own,” they said. “It could spread between humans, but not very efficiently in a way that could sustain itself onward without constantly being reintroduced from animal populations.”

That’s a big reason that public health authorities, including the WHO, are expressing confidence that cases of monkeypox will not suddenly skyrocket. “This is a containable situation,” Van Kerkhove said Monday at the public session.

Because monkeypox is closely related to smallpox, there are already vaccines

Monkeypox and smallpox are both members of the Orthopox family of viruses. Smallpox, which once killed millions of people every year, was eradicated in 1980 by a successful worldwide campaign of vaccines.

The smallpox vaccine is about 85% effective against monkeypox, the WHO says, although that effectiveness wanes over time.

“These viruses are closely related to each other, and now we have the benefit of all those years of research and diagnostics and treatments and in vaccines that will be brought to bear upon the situation now,” said Lewis of the WHO.

Some countries, including the U.S., have held smallpox vaccines in strategic reserve in case the virus ever reemerged. Now, those can be used to contain a monkeypox outbreak.

The FDA has two vaccines already approved for use against smallpox.

One, a two-dose vaccine called Jynneos, is also approved for use against monkeypox. About a thousand doses are available in the Strategic National Stockpile, the CDC says, and the company will provide more in the coming months.

“We have already worked to secure sufficient supply of effective treatments and vaccines to prevent those exposed from contracting monkeypox and treating people who’ve been affected,” said Dr. Raj Panjabi of the White House pandemic office, in an interview with NPR.

Copyright 2022 NPR. To see more, visit

Adblock test (Why?)

Source link

Continue Reading